-
1.发明公开Microrna expression signature in peripheral blood of patients affected by hepatocarcinoma or hepatic cirrhosis and uses thereof 审中-公开在肝癌患者或肝硬化和外周血微小RNA表达签名使用它们的
公开(公告)号：EP2657354A1
公开(公告)日：2013-10-30
申请号：EP13178241.9
申请日：2010-09-06
发明人： Pagani, Massimiliano , De Francesco, Raffaele , Abrignani, Sergio , Rossetti, Grazisa , Rossi, Riccardo Lorenzo
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： A method for diagnosing or prognosticating hepatocellular carcinoma, also in the early stages, or for assessing the risk of developing hepatocellular carcinoma, or for monitoring the effectiveness of an anti-tumour therapy against hepatocellular carcinoma by measuring the expression level of at least one miRNA gene product in a peripheral blood sample or in a biological fluid sample. Said method comprises measuring, in an isolated sample of peripheral blood or biological fluid, the expression level of at least one miRNA gene product, and comparing said measured expression level with a reference level. Such method can also be used to diagnose or assess the risk of developing liver cirrhosis in patients affected by chronic hepatitis, or to prognosticate the evolution of cirrhosis in patients affected by cirrhosis, or to monitor the effectiveness of a pharmacological therapy against liver cirrhosis.
摘要翻译： 一种用于诊断或预测肝细胞癌，所以在早期阶段的方法，或离开唱显影肝细胞癌的风险，或用于通过测量至少一种miRNA基因的表达水平监测对肝细胞癌的抗肿瘤治疗的有效性 产物外周血样品中或生物流体样本。 所述方法包括在外周血或生物流体分离的样品测量，至少一种miRNA基因产物的表达水平，并将其与参考电平进行比较所述测得的表达水平。 因此搜索方法可用于诊断或评估在受慢性肝炎患者发展为肝硬化的风险，或者预言在受肝硬化肝硬化的演变，或者监视对肝硬化药理疗法的有效性。
搜索结果
1 条记录 (耗时 0.01 秒)
